Half-year report · Q2
7776.TEDINET S100U7CG
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥76m | 2024-01-01 → 2024-06-30 | Standalone | Net sales |
| Revenue | ¥190m | 2023-01-01 → 2023-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥67m | 2023-01-01 → 2023-06-30 | Standalone | Net sales |
| Operating income | −¥464m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Operating income | −¥359m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Ordinary income | −¥463m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥710m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥367m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥473m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥363m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Net income | −¥474m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Net income | −¥847m | 2023-01-01 → 2023-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥364m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Total assets | ¥2.4bn | at 2024-06-30 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2023-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥311m | at 2024-06-30 | Standalone | Liabilities |
| Total liabilities | ¥301m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.1bn | at 2024-06-30 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2023-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2024-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥405m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥779m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥348m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥6m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥56m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥18m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥422m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.8bn | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥848m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-14.74 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-29.43 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.29 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 86.4% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.1% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 33,447,119 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,459,019 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,385,419 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥113m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥332m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥75m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥75m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥19m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥76m |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥76m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | −¥351m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥96m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥5m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥5m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥236m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥62m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥62m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥28m |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥67m |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥67m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | −¥263m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 433
| Item | Context | Value | Unit |
|---|---|---|---|
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)完全議決権株式であり権利内容に何ら限定のない当社における標準となる株式であります。なお、単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)日新精器株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)広島県広島市南区東雲２丁目１３番１５号 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)小野 一成 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都杉並区 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)ＪＰモルガン証券株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内２丁目７－３東京ビルディング | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)西村 彰 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)石川県金沢市 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)山本 大典 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)神奈川県横浜市保土ヶ谷区 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | BNY GCM ACCOUNTS M NOM | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | 1 ANGEL LANE, LONDON, EC4R 3AB, UNITED KINGDOM | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)三輪 禎行 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)大阪府大阪市港区 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)株式会社ＳＢＩ証券 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区六本木１丁目６番１号 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)大日本印刷株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)東京都新宿区市谷加賀町１丁目１番１号 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)安井 勝孝 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |